SCHEMBL5878049

SCHEMBL5878049

Cc1ccc(S(=O)(=O)n2nc(NC3CCC3)c3c2CC(c2ccccc2)(c2ccccn2)C=C3)cc1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.34
KDM4E B2RXH2 2/20 0.34
RAB9A P51151 1/20 0.34
USP2 O75604 1/20 0.33
MAPK1 P28482 1/20 0.33
ALDH1A1 P00352 4/20 0.32
CCR6 P51684 2/20 0.32
JAK2 O60674 1/20 0.32
JAK1 P23458 1/20 0.32
TYK2 P29597 1/20 0.32
JAK3 P52333 1/20 0.32
NR1H2 P55055 1/20 0.32
NR1H3 Q13133 1/20 0.32
NOD2 Q9HC29 1/20 0.31
NOD1 Q9Y239 1/20 0.31
POLB P06746 1/20 0.31
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31
LMNA P02545 1/20 0.31
EPHX2 P34913 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5876223 0.97 SMN1; SMN2 (0.33) SMN1; SMN2KDM4ERAB9AUSP2MAPK1
SCHEMBL5877594 0.95 RAB9A (0.35) SMN1; SMN2KDM4ERAB9AUSP2MAPK1
SCHEMBL5876505 0.92 RAB9A (0.35) SMN1; SMN2KDM4ERAB9AALDH1A1CCR6
SCHEMBL5876198 0.92 USP2 (0.37) USP2MAPK1ALDH1A1CCR6NR1H2
SCHEMBL5878064 0.91 USP2 (0.32) USP2MAPK1CCR6NR1H2NR1H3
SCHEMBL5876674 0.89 USP2 (0.35) USP2MAPK1ALDH1A1CCR6JAK2
SCHEMBL5876077 0.88 GBA1 (0.33) RAB9AUSP2MAPK1CCR6NR1H2
SCHEMBL5876012 0.88 NR1H2 (0.36) USP2MAPK1ALDH1A1CCR6NR1H2
SCHEMBL5876624 0.88 CCR6 (0.33) ALDH1A1CCR6NR1H2NR1H3MEN1
SCHEMBL5877418 0.87 ALDH1A1 (0.36) SMN1; SMN2USP2MAPK1ALDH1A1CCR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7119115-B2 Indazole or indole derivatives, and use thereof in human medicine and more particularly in oncology AVENTIS PHARMA S.A. (FR) 2006-10-10 US disclosed
US-20040162276-A1 Indazole or indole derivatives, and use thereof in human medicine and more particularly in oncology AVENTIS PHARMA S.A. (FR) 2004-08-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040162276-A1 Indazole or indole derivatives, and use thereof in human medicine and more particularly in oncology IDO1, IDO2, INMT SMN1; SMN2 4244/4885KDM4E 3189/4885RAB9A 2565/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.